AIA Group Ltd Has $1.38 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

AIA Group Ltd boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 183.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 14,933 shares of the biopharmaceutical company's stock after acquiring an additional 9,664 shares during the period. AIA Group Ltd's holdings in Gilead Sciences were worth $1,379,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. HHM Wealth Advisors LLC increased its stake in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences during the fourth quarter worth $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at about $29,000. Crews Bank & Trust bought a new position in shares of Gilead Sciences during the fourth quarter worth about $31,000. Finally, Stephens Consulting LLC grew its stake in shares of Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 260 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the business's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $12,626,253.06. The trade was a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 302,785 shares of company stock valued at $30,503,250 over the last ninety days. 0.16% of the stock is owned by company insiders.

Remove Ads

Gilead Sciences Trading Up 0.4 %

Gilead Sciences stock traded up $0.50 during trading hours on Thursday, hitting $112.39. The stock had a trading volume of 10,041,148 shares, compared to its average volume of 7,317,884. The stock has a market cap of $139.94 billion, a price-to-earnings ratio of 303.76, a P/E/G ratio of 0.71 and a beta of 0.32. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The business's 50 day simple moving average is $106.63 and its 200-day simple moving average is $95.52. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.81%. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is 854.05%.

Analysts Set New Price Targets

GILD has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Wells Fargo & Company upped their target price on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $80.00 price objective on shares of Gilead Sciences in a report on Wednesday, December 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $105.12.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.